Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... encompassing 167 patients. ISTODAX is a member of a new class of cancer drugs known as histone deacetylase (HDAC) inhibitors and is expected to be commercially available in January 2010. ...
2009 NOV 16 ... one involving the repressive protein Whi5, and the second involving Stb1. The Rpd3 histone deacetylase complex is also involved. Cln3 binds to SBF at the CLN2 promoter, and removes previously ...
2009 NOV 17 ... during cell senescence present the inverse correlation. We also find that Lsh requires histone deacetylase (HDAC) activity to repress p16(INK4a) and treatment with trichostatin A (TSA) is ...
2009 NOV 16 ... modified by acetylation and that this event is associated with a significant decrease in histone deacetylase activity and contributes to RTN-1C binding to DNA," wrote B. Fazi and colleagues, ...
2009 NOV 16 ... little effect on apoptosis induction at clinically achievable concentrations. Because histone deacetylase inhibitors (HDACIs) have been suggested to regulate signaling protein transcription and ...
2009 NOV 16 ... or DNA binding of NF-kappa B subunits. They do, however, show reduced levels of the histone deacetylase HDAC1, a negative regulator of basal NF-kappa B activity," wrote R.A. Liberatore and ...
2009 NOV 16 ... Current study results from the report, 'Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia,' ...
2009 NOV 25 ... post-training, returning to basal levels afterward. Accordingly, the administration of histone deacetylase inhibitors sodium butyrate (NaB) and trichostatin A allowed a weak training to induce ...
2009 NOV 16 ... in British Journal of Haematology. According to a study from Milan, Italy, "Unselective histone deacetylase (HDAC) inhibitors are a promising novel therapy for lymphoid malignancies. However, ...
2009 NOV 23 ... of histone deacetylases, which are up-regulated in cancer. Indeed, one of these enzymes, histone deacetylase 6 (HDAC6), influences the acetylation state of a key androgen receptor (AR) chaperone, ...
2009 NOV 23 ... histone acetylation in somatic cell nuclear transfer (SCNT) embryos, by applying a histone deacetylase (HDAC) inhibitor such as trichostatin A (TSA), significantly enhances the developmental ...
2009 NOV 16 ... and found to inhibit both cancer and control cells in equal amounts. In contrast, histone deacetylase inhibitor trichostatin A, thiram, DSF, and monensin were identified as selective ...
2009 NOV 23 ... "Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, Lee HB. Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-beta 1-induced renal ...
2009 NOV 9 ... heterochromatin protein 1, methyl-CpG binding protein 2, Enhancer of Zeste homolog 2, histone deacetylase 1, and UHRF1, but it does require an intact nucleosomal structure. We also show that ...
2009 NOV 9 ... the terminal steps, in which Ang II reprograms cardiac gene expression." "Histone deacetyltransferases (HDACs) are considered as the integrators of divergent ... of China, Harbin, Angiotensins, Angiotensin, Cardiology, Cardiomegaly, Cardiomyocyte, Deacetylase, Drugs, Enzyme Research, Experimental Medicine, Hypertrophy, Pharmaceuticals, ...
2009 NOV 16 ... stimuli that are effective at reactivating EBV can be divided into two main groups. The histone deacetylase inhibitors sodium butyrate and trichostatin A require a relatively long period of ...
2009 NOV 9 ... "This persistent increase in H3 acetylation is associated with decreased levels of histone deacetylase 2 (HDAC2) in the nucleus accumbens. Similar effects were observed in the nucleus ...
2009 NOV 9 ... the novel proapoptotic ability of oncogenic H-Ras to increase cell susceptibility to a histone deacetylase inhibitor (HDACI) FR901228 for inducing caspase activation and selective apoptosis. ...
2009 NOV 10 ... & Development report. "Heme binding to Rev-erb alpha recruits the NCoR/histone deacetylase 3 (HDAC3) corepressor complex to repress the transcription of the coactivator PGC-1 ...
